Prop. 71's fine print contains surprises: Tightly written law leaves little room for oversight or changes
By Bernadette Tansey,
San Francisco Chronicle
| 12. 08. 2004
The $3 billion stem cell initiative that passed overwhelmingly last month holds surprises for voters who didn't read it -- starting with a provision that the research money doesn't have to be spent on stem cell studies.
It's also not the case, contrary to campaign pitches for Proposition 71, that the $3 billion raised from state bonds won't cost the state anything for the first five years. Interest payments will begin immediately, paid out of the bond money itself -- meaning that tens to hundreds of millions of "research" dollars must be used to pay debt service.
And as lawmakers and critics have learned, if they find fault with the ballot initiative, changing it could be tough. Under the proposition's terms, the state Legislature can't modify the law for three years. Even then, it can do so only by a 70 percent vote of both houses and with the governor's approval.
Some laws are like a car patched together from spare parts, but the California Stem Cell Research and Cures Initiative is built like a tank. Lawyers involved in...
Related Articles
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Ed Pilkington, The Guardian | 06.12.2026
Desperate US parents paying up to $20,000 a session for a procedure scientists say could be bogus
Autistic children as young as 18 months old are being injected with human stem cells derived from umbilical cords in unapproved, unproven and...
By Tobi Thomas, The Guardian | 06.10.2026
The UK’s stem cell transplant system is potentially putting the lives of blood cancer patients at risk as a result of inadequate infrastructure and a lack of long-term planning, a parliamentary report has found.
A hematopoietic stem cell transplant, often...